Saks (SKS) (ELN) (YSI) (FE) (FMCN) (FRT) Upgraded

Saks Inc (NYSE: SKS), Elan Corp. (NYSE: ELN), U-Store-It Trust (NYSE: YSI), FirstEnergy Corp. (NYSE: FE), Focus Media (NASDAQ: FMCN) and Federal Realty Investment Trust (NYSE: FRT) upgraded by analysts.

Saks Inc (NYSE: SKS) was upgraded by Credit Suisse (NYSE:CS) from an “Underperform” rating to a “Neutral” rating.

Elan Corp. (ELN) was upgraded by Credit Suisse (CS) from a “Neutral” rating to an “Outperform” rating.

U-Store-It Trust (YSI) was upgraded by BMO Capital Markets from a “Market Perform” rating to an “Outperform” rating.

FirstEnergy Corp. (FE) was upgraded by BMO Capital Markets from a “Market Perform” rating to an “Outperform” rating.

Focus Media (FMCN) was upgraded by Deutsche Bank (NYSE:DB) from a “Hold” rating to a “Buy” rating.

Federal Realty Investment Trust (FRT) was upgraded by Raymond James (NYSE:RJF) from a “Market Perform” rating to an “Outperform” rating.

Elan (NYSE:ELN) Pressured by Gilenya Launch

Elan Corp (NYSE:ELN) will be under pressure as a result of the impressive launch of Novartis' (NYSE:NVS) oral MS drug Gilenya.

Barclays noted, "We are maintaining our rating on Elan following review of SDI VONA prescription data, with focus on a strong U.S. launch of Novartis' (NYSE:NVS) oral MS drug Gilenya and its negative impact on Elan (NYSE:ELN) / Biogen's (Nasdaq:BIIB) Tysabri. The proprietary physician-level data from ImpactRx demonstrate that Gilenya, which was launched in October, has captured 23% of New Written Prescription Starts (NWRx) in November among neurologists. For Tysabri, we estimate that its NWRx share has fallen to 7% in November from 13% for YTD September period."

Barclays maintains an "Equalweight" on Elan Corp., which closed Friday at $6.00, up $0.15, or 2.56 percent. Barclays has a price target of $6 on them.